PDS Planning’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$316K Sell
8,587
-5,789
-40% -$274K 0.02% 380
2025
Q4
$731K Buy
14,376
+2,639
+22% +$135K 0.05% 187
2025
Q3
$651K Sell
11,737
-1,806
-13% -$106K 0.05% 199
2025
Q2
$935K Sell
13,543
-309
-2% -$21K 0.07% 137
2025
Q1
$962K Buy
13,852
+546
+4% +$45.1K 0.08% 108
2024
Q4
$1.14M Buy
13,306
+184
+1% +$19.9K 0.1% 89
2024
Q3
$1.56M Buy
13,122
+723
+6% +$96.4K 0.14% 72
2024
Q2
$1.77M Buy
12,399
+251
+2% +$33.3K 0.18% 65
2024
Q1
$1.56M Buy
12,148
+408
+3% +$48.6K 0.16% 66
2023
Q4
$1.21M Buy
11,740
+56
+0.5% +$5.54K 0.14% 69
2023
Q3
$1.06M Buy
11,684
+688
+6% +$60.6K 0.14% 73
2023
Q2
$890K Buy
10,996
+272
+3% +$22.2K 0.11% 83
2023
Q1
$853K Buy
10,724
+3,280
+44% +$233K 0.12% 79
2022
Q4
$504K Buy
7,444
+184
+3% +$10.8K 0.08% 94
2022
Q3
$362K Sell
7,260
-246
-3% -$13.2K 0.07% 113
2022
Q2
$418K Buy
7,506
+1,978
+36% +$110K 0.08% 110
2022
Q1
$307K Buy
5,528
+846
+18% +$43.4K 0.05% 143
2021
Q4
$262K Sell
4,682
-496
-10% -$26.9K 0.05% 154
2021
Q3
$249K Sell
5,178
-250
-5% -$12.1K 0.06% 154
2021
Q2
$227K Buy
+5,428
New +$210K 0.06% 163

Other funds holding NVO

PDS Planning's NVO Position: Q1 2026 in Review

PDS Planning reduced its Novo Nordisk (NVO) stake by 40% in Q1 2026, selling an estimated $274K and leaving 8,587 shares worth $316K. The position accounts for 0.02% of the portfolio, ranked #380.

PDS Planning first reported a position in NVO in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.77M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • PDS Planning held 8,587 shares of Novo Nordisk worth $316K as of Q1 2026.
  • PDS Planning sold 5,789 Novo Nordisk shares in Q1 2026, an estimated $274K.
  • Novo Nordisk made up 0.02% of PDS Planning's portfolio in Q1 2026, its #380 holding.
  • PDS Planning first reported a position in Novo Nordisk in Q2 2021 and has held it in 20 quarters since.
  • PDS Planning's Novo Nordisk position peaked at $1.77M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on PDS Planning's 13F filing for Q1 2026, filed 22 Apr 2026.